Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor

Köse, Osman; Taştan, Halis Bülent; Gür, Ali Rıza; Kurumlu, Zafer

doi:10.1080/095466302317584430

Cited by 25 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Itraconazole, a triazole antifungal, alters fungal cell function similarly to ketoconazole, through inhibition of cytochrome P450-dependent ergosterol synthesis [ 28 ]. To effectively treat PV, a minimum total amount of 1000 mg itraconazole over the course of treatment was required to produce a significant mycological response [ 51 ]. Treatment once daily for 5 days with 200 mg itraconazole shows high efficacy up to one month following treatment [ 47 , 50 ] and is recommended for treatment of PV [ 62 ].…”

Section: Oral Treatment For Pityriasis Versicolormentioning

confidence: 99%

“…Studies have evaluated the efficacy of 400 mg itraconazole administered once and for 3 days as compared to 200 mg itraconazole for 5 or 7 days [ 50 , 51 ]. While Kose et al (2002) demonstrated that a single 400 mg dose was equivalent to 200 mg for 7 days [ 51 ], Kokturk et al (2002) found a single 400 mg dose to be ineffective, with itraconazole regimens of 400 mg for 3 days and 200 mg for 5 days both producing significantly greater mycological and complete cure ( p = 0.001) [ 50 ]. Although a regimen of 400 mg itraconazole for 3 days may be an alternative to 200 mg itraconazole for 5 days, there is not enough evidence at this time to warrant changing recommendations from 5 day treatment.…”

Section: Oral Treatment For Pityriasis Versicolormentioning

confidence: 99%

See 1 more Smart Citation

Antifungal Treatment for Pityriasis Versicolor

Gupta

Foley

2015

JoF

View full text Add to dashboard Cite

Background: Pityriasis versicolor (PV), also known as tinea versicolor, is caused by Malassezia species. This condition is one of the most common superficial fungal infections worldwide, particularly in tropical climates. PV is difficult to cure and the chances for relapse or recurrent infections are high due to the presence of Malassezia in the normal skin flora. This review focuses on the clinical evidence supporting the efficacy of antifungal treatment for PV. Method: A systematic review of literature from the PubMed database was conducted up to 30 September 2014. The search criteria were “(pityriasis versicolor OR tinea versicolor) AND treatment”, with full text available and English language required. Conclusions: Topical antifungal medications are the first-line treatment for PV, including zinc pyrithione, ketoconazole, and terbinafine. In cases of severe or recalcitrant PV, the oral antifungal medications itraconazole and fluconazole may be more appropriate, with pramiconazole a possible future option. Oral terbinafine is not effective in treating PV and oral ketoconazole should no longer be prescribed. Maintenance, or prophylactic, therapy may be useful in preventing recurrent infection; however, at this time, there is limited research evaluating the efficacy of prophylactic antifungal treatment.

show abstract

Section: Oral Treatment For Pityriasis Versicolormentioning

confidence: 99%

Section: Oral Treatment For Pityriasis Versicolormentioning

confidence: 99%

Antifungal Treatment for Pityriasis Versicolor

Gupta

Foley

2015

JoF

View full text Add to dashboard Cite

show abstract

“…Multiple randomized trials have reported 70-100 % mycologic cure with 200 mg itraconazole daily for 7 days [39]. In a randomized, open-label trial, a single 400-mg dose of itraconazole was as effective as 200 mg daily for 7 days [47]. The evidence is also strong for 300 mg fluconazole weekly for up to 2 weeks, which resulted in mycologic cure for 87 % of patients [48].…”

Section: Tinea (''Pityriasis'') Versicolormentioning

confidence: 95%

Skin Conditions of Baseball, Cricket, and Softball Players

et al. 2013

View full text Add to dashboard Cite

Each year in the United States over 80 million people participate in bat-and-ball sports, for example baseball and softball. Cricket, the world's second most popular sport, is enjoyed by hundreds of millions of participants in such countries as India, Pakistan, Australia, New Zealand, Bangladesh, South Africa, West Indies, Sri Lanka, United Kingdom, and Zimbabwe. Although any player can develop skin disease as a result of participation in these bat-and-ball sports, competitive team athletes are especially prone to skin problems related to infection, trauma, allergy, solar exposure, and other causes. These diseases can produce symptoms that hinder individual athletic performance and participation. In this review, we discuss the diagnosis and best-practice management of skin diseases that can develop as a result of participation in baseball, softball, and cricket.

show abstract

“…İtrakonazol pitriazis versikolor tedavisinde yüksek etkinlik gösterir. Köse ve ark, erişkinlerde bir günlük 400 mg itrakonazol dozunu, 7 günlük 200 mg/gün itrakonazole etkinlik ve güvenilirlik açısından eşit bulmuşlardır 45 . Çocuklar için önerilen itrakonazol dozu < 50 kg çocuklarda 1 haftalık tek kür 5mg/kg/gün, ≥ 50 kg çocuklarda 200 mg/gün önerilir 20 .…”

Section: Tedaviunclassified

Childhood Fungal Infections

Gür¹

2011

Turkderm

View full text Add to dashboard Cite

ÖzetFungal infeksiyonlar yüzeyel formlardan, derin ve sistemik formlara doğru geniş bir spektrumu kapsarlar. Çocuklarda, fungal infeksiyonların klinik özellikleri ve sıklıkları erişkinlere göre değişkenlik gösterir. Klinik şüphe ve doğru tanı aşamalarından sonra etkin tedavi basamağına geldiğimizde ise fungal enfeksiyonlarla olan savaşımızın dinamik bir süreç olduğunu görüyoruz Direnç gelişimi, farklı türlere daha sık rastlanması, daha etkin ama daha az yan etkili doz şemaları, yeni ilaçlar, hastalarımızı izlerken dikkat edilmesi gereken noktalar olup, bilgilerimizi güncel tutmamızı gerektiren başlıca nedenlerdir Etkene yönelik doğru antifungalin seçilmesi, uygun doz planlamasının yapılması, ve optimal hasta takibiyle kür sağlanması hem morbiditeyi azaltmakta, hem de derin ve sistemik formlarda mortaliteyi önlemiş olmaktadır. Bu yazıda, çocukluk çağında görülen özellikleri vurgulanarak, dermatofitozlar, piedra, Malessezia enfeksiyonları, Candida infeksiyonları, ve immünyetmezlik durmunuda rastlanan derin kutanöz fungal enfeksiyonların genel özellikleri ve tedavileri anlatılmıştır. Sum maryFungal infections cover a wide spectrum from superficial forms to deep cutaneous and systemic forms. The prevalance and clinical characteristics of fungal infections differ in children from adults. We realize the dynamic nature of our war against fungal infections when we reach the treatment phase after appropriate clinical suspicion and correct diagnosis. Emergence of resistance, different strains becoming more prevalant, more efficient but less toxic drug schemes, new drugs, tips on optimal follow up of our patients are the reasons why we have to keep our knowledge on antifungals up to date. Successful cure by organism based choise of the right antifungal, appropriate dose planning and optimal patient follow up resulting in cure will not only decline morbidity but also prevent mortality in deep and systemic forms. Here in this article, dermatophytoses, piedra, Malassezia infections, Candida infections, and major characteristics of deep cutaneous fungal infections in immune compromised children and their relevant treatments are discussed.

show abstract

Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor

Abstract: On the basis of these findings, a single dose of itraconazole 400 mg/day was as effective as the 7-day 200 mg daily dose in the treatment of pityriasis versicolor.

Cited by 25 publications

References 9 publications

Antifungal Treatment for Pityriasis Versicolor

Antifungal Treatment for Pityriasis Versicolor

Skin Conditions of Baseball, Cricket, and Softball Players

Childhood Fungal Infections

Contact Info

Product

Resources

About